BioSpace News Archive

Highly Multiplexed Target Enrichment Panel Covers Entire Genome of the New Coronavirus to Facilitate Complete Genome Sequencing and Support Epidemiological Studies

BELLUS Health Inc. announced that it has completed patient enrollment for the RELIEF trial, its dose-escalation, placebo-controlled Phase 2 trial of BLU-5937 in patients with refractory chronic cough.

Transaction supports FORMA’s business model transition from early research focus to integrated biopharma company with research, development and commercial capacity

Company Builds Leadership Team for Next Stage of Growth with Expanded Commercialization of Organs-on-Chips Product Suite

Platform adopted by 10 of the top 25 biopharmaceutical companies, by U.S. governmental agencies, and by academic research centers worldwide

Mateon Therapeutics, Inc. (OTCQB:MATN) (“Mateon”) announced today their expanded focus on artificial intelligence (AI) enabled EdgePoint projects by expanding their partnership with Meridian IT, a leading technology services provider. EdgePoint, the AI division of Mateon, was formed after the acquisition of PointR Data, Inc., that specializes in AI machine vision for the retail sector. In retail, the underlying Amazon

ChroniSense Medical, developer of Polso™, a wearable, medical-grade, disease management device for multiple clinical applications, announced the appointment of Bridget Ross as Chief Executive Officer (CEO) effective February 10, 2020.

MYOS RENS Technology Inc. will announce financial results for the fourth quarter of 2019 on Wednesday, March 25 at 11 AM (ET

Clinical trial for patients failing checkpoint therapy uses combination of first-in-class, cryopreserved, CD16 NK cells, ImmunityBio’s IL-15 superagonist and checkpoint inhibitor Avelumab EL SEGUNDO, Calif.--( BUSINESS WIRE )-- NantKwest, Inc. (Nasdaq: NK), a next-generation, clinical-stage immunotherapy company focused on harnessing the unique power of our immune system using natural killer (NK) cells to treat cancer and infectious diseases, today

Cassava Sciences, Inc. today announced clinical updates and business progress across its pipeline of product candidates under development.